力諾藥包(301188.SZ)擬在巴西設立境外控股子公司 註冊資本200萬美元
格隆匯3月10日丨力諾藥包(301188.SZ)公佈,爲進一步開拓海外市場,滿足國際客戶的需求,完善產品在全球市場的供應能力,公司於2025年3月10日在山東濟南與SANTISA LABORATóRIO FARMACêUTICO S/A(以下簡稱"SANTISA")簽訂了《合作投資協議》。公司與SANTISA雙方擬在巴西共同設立力諾醫藥包裝巴西有限公司(暫定名稱,以下簡稱"巴西藥包"),經營範圍爲生產、銷售醫藥包裝產品,包括安瓿瓶和西林瓶等。巴西藥包註冊資本爲200萬美元,其中,公司將持有其75%的股份,SANTISA將持有其25%的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.